Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 2, 2012, Pages 517-520

  Suprasert, Prapaporn ^a   Cheewakriangkrai, Chalong ^a   Manopunya, Manatsawee ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; PLATINUM COMPLEX;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CYSTADENOCARCINOMA; DRUG EFFECT; DRUG RESISTANCE; ENDOMETRIUM TUMOR; FEMALE; FOLLOW UP; HUMAN; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL RATE; TUMOR RECURRENCE; UTERINE TUBE TUMOR;

ADENOCARCINOMA; ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CYSTADENOCARCINOMA, SEROUS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE;

EID: 84866463864     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.2.517     Document Type: Article

References (16)

1. Distefano M, Ferlini C, De Vincenzo R, et al (2001). Antagonistic effect of the combination gemcitabine/topotecan in ovarian cancer cells. Oncol Res, 12, 335-59.
2. Hahnvajanawong C, Bhudisawadi V, Namwat N, et al (2011). Comparative in vitro cytotoxicity of the generic and reference products of gemcitabine on various cancer cell lines. Srinagarind Med J, 26, 1-8.
3. Huang P, Chubb S, Hertel L, et al (1991). Action of 2_,2_-diflurodeoxycytidine on DNA synthesis. Cancer Res, 51, 6110-7.
4. Heinemann V, Xu YZ, Chubb S, et al (1990). Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2_,2_-difluorodeoxycytidine. Mol Pharmacol, 38, 567-72.
5. Heinemann V, Hertel LW, Grindey GB, et al (1988). Comparison of the cellular pharmacokinetics and toxicity of 2_,2_-difluorodeoxycytidine and 1-beta-d-arabinofuranosyl cytosine. Cancer Res, 48, 4024-31.
6. Lorusso D, Di Stefano A, Fanfani F, et al (2006). Role of gemcitabine in ovarian cancer treatment. Ann Oncol, 17, 188-94.
7. Mutch DG, Orlando M, Goss T, et al (2007). Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol, 25, 2811-8.
8. Mackey JR, Mani RS, Selner M, et al (1998). Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res, 58, 4349-57.
9. Miller AB, Hoogstraten B, Staquet M, et al (1981). Reporting results of cancer treatment. Cancer, 47, 207-14.
10. Ojeda Gonzalez B, Gonzalez Martin A, Bover Barcelo I, et al (2008). A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial. Am J Clin Oncol, 31, 481-7.
11. Peters GJ, Bergman AM, Ruiz van Haperen VW, et al (1995). Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol, 22, 72-9.
12. Rustin GJ, Vergote I, Eisenhauer E, et al (2011). Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer, 21, 419-23.
13. Ruiz van Haperen VW, Veerman G, Boven E, et al (1994). Schedule dependence of sensitivity to 29,29-difluorodeoxycytidine-(gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol, 48, 1327-39.
14. Ruiz van Haperen VW, Veerman G, Vermorken JB, et al (1993). 2',2'-Diflurodeoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines. Biochem Pharmacol, 46, 762-6.
15. Van Moorsel CJ, Peters GJ, Pinedo HM (1997). Gemcitabine: future prospects of single-agent and combination studies. Oncologist, 2, 127-34.
16. Watanabe Y, Koike E, Nakai H, et al (2008). Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer. Int J Clin Oncol, 13, 345-8.